With a staggering $7.2 billion allocated to the National Cancer Institute last year, it's time to pull back the curtain on where the immense fight against cancer is being funded and if this financial firepower is truly hitting its mark.
Key Takeaways
- In fiscal year 2023, the National Cancer Institute (NCI) received a budget of $7.2 billion for cancer research, marking a 5.3% increase from FY2022
- The NCI allocated $1.1 billion to cancer biology research in FY2022, representing 16% of its total research budget
- From 2018 to 2022, NCI extramural grants for cancer research averaged $5.8 billion annually, supporting over 5,000 awards
- American Cancer Society (ACS) invested $150 million in research grants in 2022, funding 700+ projects worldwide
- Susan G. Komen Foundation granted $80 million for breast cancer research in 2023
- Stand Up To Cancer awarded $500 million since 2008 to collaborative cancer projects
- World Cancer Research Fund International granted £50 million ($65M) since 1981 for diet-cancer links
- European Union's Horizon Europe program allocated €1 billion ($1.1B) for cancer research 2021-2027
- Cancer Research UK total funding £2 billion over 10 years to 2023
- In 2022, NCI allocated $800 million to breast cancer research, 11% of total budget
- Prostate cancer received $350 million from NCI in FY2023, focusing on disparities
- Lung cancer NCI funding totaled $450 million in 2022, highest for any type due to incidence
- NCI cancer research funding grew 70% from $4.1 billion in 2010 to $7.0 billion in 2020
- Global cancer research investment rose from $50 billion in 2010 to $120 billion in 2022, CAGR 7%
- US private philanthropy for cancer increased 15% annually 2015-2023 to $5 billion yearly
Cancer research funding spans billions across federal programs, foundations, and global initiatives.
Funding Allocation by Cancer Type
- In 2022, NCI allocated $800 million to breast cancer research, 11% of total budget
- Prostate cancer received $350 million from NCI in FY2023, focusing on disparities
- Lung cancer NCI funding totaled $450 million in 2022, highest for any type due to incidence
- Colorectal cancer got $300 million NCI allocation in FY2023 for screening tech
- Pancreatic cancer NCI funding was $220 million in 2022, despite low survival
- Leukemia/lymphoma NCI grants summed $400 million in FY2023
- Brain cancer (CNS) received $250 million from NCI in 2022 for gliomas
- Ovarian cancer NCI allocation $180 million FY2023, targeting PARP inhibitors
- Liver cancer funding by NCI was $150 million in 2022, rising due to hep B/C links
- Melanoma NCI grants $280 million in FY2023 for immunotherapy advances
- Childhood cancers (all) NCI pediatric funding $250 million in 2022
- Head and neck cancers NCI $120 million FY2023
- Bladder cancer NCI allocation $100 million in 2022
- Kidney (renal) cancer $140 million NCI 2023
- Esophageal cancer NCI funding $80 million FY2022
- Stomach (gastric) cancer $90 million NCI 2023
- Thyroid cancer NCI grants $70 million 2022
- Multiple myeloma NCI $110 million FY2023
- Non-Hodgkin lymphoma $200 million NCI 2022
- Cervical cancer NCI allocation $60 million 2023 HPV focus
- Uterine/endometrial $75 million NCI FY2022
- Testicular cancer $40 million NCI 2023
- Soft tissue sarcoma $50 million NCI 2022
- Mesothelioma $30 million NCI FY2023
Funding Allocation by Cancer Type Interpretation
While funding reflects the brutal arithmetic of incidence and mortality, these numbers map a determined, if imperfect, battle plan against a cunning and varied enemy.
Historical Trends and Projections
- NCI cancer research funding grew 70% from $4.1 billion in 2010 to $7.0 billion in 2020
- Global cancer research investment rose from $50 billion in 2010 to $120 billion in 2022, CAGR 7%
- US private philanthropy for cancer increased 15% annually 2015-2023 to $5 billion yearly
- NCI budget as % of NIH total declined from 20% in 2000 to 15% in 2023 despite absolute growth
- DoD cancer research funding tripled from $50 million in 2000 to $150 million in 2022
- Cancer immunotherapy funding exploded from $1B in 2015 to $20B in 2023 globally
- CAR-T cell therapy R&D investment reached $10 billion cumulative by 2023 from 2017 start
- NCI projections estimate $8.5 billion budget by FY2027 under current trends
- Pharma oncology R&D spend projected to hit $150 billion by 2028 from $100B 2023
- Pediatric cancer funding stagnant at $250M NCI level since 2015 adjusted for inflation
- Global south cancer research funding grew 200% 2010-2022 to $2 billion annually
- Precision oncology grants doubled from 1,000 in 2018 to 2,500 in 2023 NCI-wide
- Cancer survival rates improved 30% since 1990 correlating with funding rise
- EU cancer research funding projected €4 billion under Horizon 2028-2034
- Venture capital in cancer biotech fell 40% in 2023 from 2021 peak of $25B
- NCI extramural awards increased 20% from 4,500 in 2015 to 5,400 in 2023
- Philanthropic funding for rare cancers up 50% since 2020 to $500M globally
- Cancer Moonshot funding legacy: $2B total 2016-2023, projected $3B more
- Inflation-adjusted NCI budget flat 2010-2020 before 5% annual rises post-2021
- International collaborative trials funding tripled to 500 projects 2015-2023
- mRNA cancer vaccine funding surged $5B since 2020 COVID tech transfer
Historical Trends and Projections Interpretation
While we've armed our global war on cancer with a truly staggering arsenal of capital—where even the DoD's efforts have tripled and immunotherapy enjoys a meteoric, twenty-fold boom—it remains a conflict fought with uneven ammunition, as seen in the stubborn stagnation of pediatric funding and the fact that the NCI's share of the NIH pie has actually shrunk, proving that even in a gold rush, some trenches are still under-resourced.
International Funding
- World Cancer Research Fund International granted £50 million ($65M) since 1981 for diet-cancer links
- European Union's Horizon Europe program allocated €1 billion ($1.1B) for cancer research 2021-2027
- Cancer Research UK total funding £2 billion over 10 years to 2023
- Canadian Cancer Society invested CAD 1.2 billion ($900M USD) since 1938, CAD 50M yearly
- INSERM France allocated €500 million ($550M) for cancer research in 2022 national plan
- German Cancer Aid provided €400 million ($440M) since 1980, €40M in 2023
- Japan Agency for Medical Research and Development (AMED) funded ¥100 billion ($700M) for cancer 2015-2023
- Australian NHMRC granted AUD 300 million ($200M USD) for cancer research 2022-2023
- Brazilian National Cancer Institute (INCA) budget R$1 billion ($200M USD) annually for research
- Indian Council of Medical Research (ICMR) allocated INR 5,000 crore ($600M) for oncology 2021-2026
- South African Medical Research Council funded ZAR 200 million ($12M USD) for cancer in 2023
- China National Natural Science Foundation cancer grants totaled CNY 10 billion ($1.4B) in 2022
- WHO's International Agency for Research on Cancer (IARC) budget $60 million in 2023 for global epidemiology
- EU Mission on Cancer invested €400 million ($440M) for pediatric cancers 2022-2027
- UK NIHR funded £200 million ($250M) for cancer trials in 2023
- Israel's Ministry of Health cancer research budget NIS 500 million ($135M) in 2023
- Russian Science Foundation granted RUB 5 billion ($55M) for oncology 2022
- Mexico's CONACYT funded MXN 1 billion ($50M) for cancer genomics 2021-2024
- Singapore NMRC allocated SGD 100 million ($75M) for precision oncology 2023
- WHO Special Initiative for NCDs provided $100 million for low-middle income cancer research 2022
- Global Cancer Observatory (GLOBOCAN) funded by IARC with $20 million annually for data
- EU 4th Cancer Framework Programme invested €1.2 billion 2021-2027
International Funding Interpretation
Despite the colossal global investment in cancer research, which resembles a frenzied international bake-off with everyone furiously mixing their own funding recipes, the sobering truth remains that we're still just scratching the surface of this complex disease.
Private Sector Funding
- American Cancer Society (ACS) invested $150 million in research grants in 2022, funding 700+ projects worldwide
- Susan G. Komen Foundation granted $80 million for breast cancer research in 2023
- Stand Up To Cancer awarded $500 million since 2008 to collaborative cancer projects
- Leukemia & Lymphoma Society funded $1.3 billion historically, with $100 million in 2022 for blood cancers
- Cancer Research UK provided £600 million ($750 million USD) annually for cancer research in 2023
- Damon Runyon Cancer Research Foundation granted $50 million in 2022 to early-career scientists
- Lustgarten Foundation allocated $30 million for pancreatic cancer since 2002, peaking at $10 million in 2023
- V Foundation for Cancer Research awarded $350 million total by 2023, $40 million in 2022
- Breast Cancer Research Foundation granted $75 million in 2023 for metastasis and subtypes
- Alex's Lemonade Stand Foundation funded $250 million for pediatric cancer since 2005, $25 million in 2023
- Congressionally Directed Medical Research Program private partnerships added $20 million matching funds in 2022
- Gateway for Cancer Research provided $40 million for innovative projects since 2004
- Melville Trust awarded $15 million for urologic cancer research in 2023
- Hyundai Hope On Wheels granted $20 million for pediatric cancer in 2022
- Swim Across America funded $10 million annually for cancer research grants in 2023
- The Hope Foundation provided $50 million for global cancer research partnerships in 2022
- Ludwig Cancer Research invested $1.5 billion since 1971, $100 million yearly average
- Terry Fox Foundation granted CAD 800 million ($600M USD) for cancer research since 1988
- Cancer Research Institute allocated $40 million for immunotherapy in 2023
- Ovarian Cancer Research Alliance funded $100 million since 1997, $12 million in 2023
- Mesothelioma Applied Research Foundation granted $20 million total by 2023
- Rally Foundation awarded $10 million for pediatric cancer since 2006
- Polaris Pharmaceuticals private funding for AML research hit $15 million in 2022
- PhRMA member companies invested $12 billion in oncology R&D in 2022
- Biotech firms received $5 billion VC funding for cancer therapies in 2023
Private Sector Funding Interpretation
While these staggering figures reveal a powerful and well-funded army fighting cancer on multiple fronts, one can't help but feel we’re still funding the siege of a formidable castle with far too many secret passages and an infuriating habit of rebuilding its walls overnight.
US Federal Funding
- In fiscal year 2023, the National Cancer Institute (NCI) received a budget of $7.2 billion for cancer research, marking a 5.3% increase from FY2022
- The NCI allocated $1.1 billion to cancer biology research in FY2022, representing 16% of its total research budget
- From 2018 to 2022, NCI extramural grants for cancer research averaged $5.8 billion annually, supporting over 5,000 awards
- In 2021, the NCI's Cancer Moonshot initiative received $1.8 billion in additional funding over 7 years, focusing on immunotherapy and early detection
- NCI intramural research funding reached $570 million in FY2023, funding 1,200 scientists across 60 labs
- The Department of Defense (DoD) Congressionally Directed Medical Research Program allocated $142 million to breast cancer research in FY2022
- DoD prostate cancer research funding totaled $100 million in FY2023 under the Peer Reviewed Cancer Research Program
- VA's National Oncology Research Program provided $50 million for cancer research in 2022, targeting veteran-specific cancers
- In 2020, ARPA-H announced $500 million for cancer innovation through the Cancer Moonshot
- NCI's SBIR/STTR program awarded $150 million to small businesses for cancer tech in FY2022
- CDC's National Comprehensive Cancer Control Program funded $60 million across 50 states in 2023 for prevention research
- FDA's Oncology Center of Excellence received $40 million in FY2023 for regulatory science in cancer drugs
- NIH's total cancer research funding outside NCI was $300 million in 2022 from other institutes like NIAID
- In FY2021, NCI training grants supported 4,500 fellows with $250 million for cancer research careers
- BRAIN Initiative allocated $20 million to neuro-oncology research in 2023 as part of NCI collaboration
- Precision Medicine Initiative (All of Us) provided $100 million for cancer genomics in 2022
- NCI's Community Oncology Research Program (NCORP) received $100 million in FY2023 for community-based trials
- DoD ovarian cancer research funding was $25 million in FY2022
- NCI's Applied Research Program funded $80 million for health services research in cancer in 2021
- In 2023, NCI surveillance funding through SEER program was $120 million, covering 48% population coverage
- HRSA's cancer programs in rural areas received $30 million in 2022 for research access
- NCI's Cancer Centers Program supported 72 centers with $450 million in FY2023
- DoD lung cancer research got $40 million in FY2023
- NCI's Pediatric Oncology Program funded $150 million in 2022 for childhood cancers
- In FY2022, NCI epidemiology research allocation was $350 million
- BARDA invested $200 million in cancer vaccine development in 2023
- NCI's Rare Cancer Research Program provided $50 million for 200+ rare types in 2021
- DoD pancreatic cancer funding reached $30 million in FY2022
- NCI's Behavioral Research Program got $120 million in FY2023 for lifestyle interventions
- In 2022, NCI clinical trials support totaled $800 million across 1,000+ trials
US Federal Funding Interpretation
The sheer magnitude of cancer funding, from billions for moonshots to millions for a single rare type, paints a picture of a nation marshalling every conceivable financial weapon against an enemy that demands no less than a full-scale economic siege.
Sources & References
- Reference 1CANCERcancer.govVisit source
- Reference 2REPORTERreporter.nih.govVisit source
- Reference 3CDMRPcdmrp.health.milVisit source
- Reference 4RESEARCHresearch.va.govVisit source
- Reference 5ARPA-Harpa-h.govVisit source
- Reference 6SBIRsbir.cancer.govVisit source
- Reference 7CDCcdc.govVisit source
- Reference 8FDAfda.govVisit source
- Reference 9REPORTreport.nih.govVisit source
- Reference 10BRAININITIATIVEbraininitiative.nih.govVisit source
- Reference 11ALLOFUSallofus.nih.govVisit source
- Reference 12NCORPncorp.cancer.govVisit source
- Reference 13CANCERCONTROLcancercontrol.cancer.govVisit source
- Reference 14SEERseer.cancer.govVisit source
- Reference 15HRSAhrsa.govVisit source
- Reference 16CANCERCENTERScancercenters.cancer.govVisit source
- Reference 17EPIepi.grants.cancer.govVisit source
- Reference 18MEDICALCOUNTERMEASURESmedicalcountermeasures.govVisit source
- Reference 19CANCERcancer.orgVisit source
- Reference 20KOMENkomen.orgVisit source
- Reference 21STANDUPTOCANCERstanduptocancer.orgVisit source
- Reference 22LLSlls.orgVisit source
- Reference 23CANCERRESEARCHUKcancerresearchuk.orgVisit source
- Reference 24DAMONRUNYONdamonrunyon.orgVisit source
- Reference 25LUSTGARTENlustgarten.orgVisit source
- Reference 26Vv.orgVisit source
- Reference 27BCRFbcrf.orgVisit source
- Reference 28ALEXSLEMONADEalexslemonade.orgVisit source
- Reference 29GATEWAYCRgatewaycr.orgVisit source
- Reference 30MELVILLETRUSTmelvilletrust.orgVisit source
- Reference 31HYUNDAINEWShyundainews.comVisit source
- Reference 32SWIMACROSSAMERICAswimacrossamerica.orgVisit source
- Reference 33THEHOPEFOUNDATIONthehopefoundation.orgVisit source
- Reference 34LUDWIGCANCERRESEARCHludwigcancerresearch.orgVisit source
- Reference 35TERRYFOXterryfox.orgVisit source
- Reference 36CANCERRESEARCHcancerresearch.orgVisit source
- Reference 37OCRAHOPEocrahope.orgVisit source
- Reference 38CUREMESOcuremeso.orgVisit source
- Reference 39RALLYFOUNDATIONrallyfoundation.orgVisit source
- Reference 40POLARISPHARMApolarispharma.comVisit source
- Reference 41PHRMAphrma.orgVisit source
- Reference 42BIOSPACEbiospace.comVisit source
- Reference 43WCRFwcrf.orgVisit source
- Reference 44ECec.europa.euVisit source
- Reference 45CANCERcancer.caVisit source
- Reference 46INSERMinserm.frVisit source
- Reference 47DEUTSCHLANDKREBSSTIFTUNGdeutschlandkrebsstiftung.deVisit source
- Reference 48AMEDamed.go.jpVisit source
- Reference 49NHMRCnhmrc.gov.auVisit source
- Reference 50INCAinca.gov.brVisit source
- Reference 51ICMRicmr.gov.inVisit source
- Reference 52SAMRCsamrc.ac.zaVisit source
- Reference 53NSFCnsfc.gov.cnVisit source
- Reference 54IARCiarc.who.intVisit source
- Reference 55RESEARCH-AND-INNOVATIONresearch-and-innovation.ec.europa.euVisit source
- Reference 56NIHRnihr.ac.ukVisit source
- Reference 57HEALTHhealth.gov.ilVisit source
- Reference 58RSCFrscf.ruVisit source
- Reference 59CONAHCYTconahcyt.mxVisit source
- Reference 60NMRCnmrc.gov.sgVisit source
- Reference 61WHOwho.intVisit source
- Reference 62GCOgco.iarc.frVisit source
- Reference 63CANCER-EUROPEcancer-europe.euVisit source
- Reference 64NATUREnature.comVisit source
- Reference 65MCKINSEYmckinsey.comVisit source
- Reference 66CBOcbo.govVisit source
- Reference 67IQVIAiqvia.comVisit source
- Reference 68STJUDEstjude.orgVisit source
- Reference 69UICCuicc.orgVisit source
- Reference 70OCGocg.cancer.govVisit source
- Reference 71RARECANCERSrarecancers.org.auVisit source
- Reference 72KFFkff.orgVisit source
- Reference 73CLINICALTRIALSclinicaltrials.govVisit source
- Reference 74MODERNATXmodernatx.comVisit source